Received Apr 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 2G273 | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | K4JH7 | — |
accidentally received a dose of Pediarix and Engerix-B administration (same day); This non-serious case was reported by a other health professional via call center representative and described the occurrence of accidental overdose in a 4-month-old female patient who received DTPa-HBV-IPV (Pediarix) (batch number 2G273) for prophylaxis. Co-suspect products included HBV (Engerix B) (batch number K4JH7) for prophylaxis. On 08-APR-2025, the patient received Pediarix and Engerix B. On 08-APR-2025, an unknown time after receiving Pediarix and Engerix B, the patient experienced accidental overdose (Verbatim: accidentally received a dose of Pediarix and Engerix-B administration (same day)). The outcome of the accidental overdose was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 08-APR-2025 The office manager called and reported that the patient was accidentally received a dose of Pediarix as well as Hepatitis B (Engerix-B) at the same time, which led to accidental overdose for hepatitis B antigen. The Vaccine Administration Facility is the same as Primary Reporter.